Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births.
Open accessThe DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malformations in infants has been the subject of much discussion and controversy. The aim of this study is to systematically review the associations between SSRIs use during early pregnancy and the risk of congenital malformations, with particular attention to the potential confounding by indication. METHODS: The study protocol was registered with PROSPERO (CRD42018088358). Cohort studies on congenital malformations in infants born to mothers with first-trimester exposure to SSRIs were identified via PubMed, Embase, Web of Science, and the Cochrane Library databases through 17 January 2018. Random-effects models were used to calculate summary relative risks (RRs). RESULTS: Twenty-nine cohort studies including 9,085,954 births were identified. Overall, use of SSRIs was associated with an increased risk of overall major congenital anomalies (MCAs, RR 1.11, 95% CI 1.03 to 1.19) and congenital heart defects (CHD, RR 1.24, 95% CI 1.11 to 1.37). No significantly increased risk was observed when restricted to women with a psychiatric diagnosis (MCAs, RR 1.04, 95% CI 0.95 to 1.13; CHD, RR 1.06, 95% CI 0.90 to 1.26). Similar significant associations were observed using maternal citalopram exposure (MCAs, RR 1.20, 95% CI 1.09 to 1.31; CHD, RR 1.24, 95% CI 1.02 to 1.51), fluoxetine (MCAs, RR 1.17, 95% CI 1.07 to 1.28; CHD, 1.30, 95% CI 1.12 to 1.53), and paroxetine (MCAs, RR 1.18, 95% CI 1.05 to 1.32; CHD, RR 1.17, 95% CI 0.97 to 1.41) and analyses restricted to using women with a psychiatric diagnosis were not statistically significant. Sertraline was associated with septal defects (RR 2.69, 95% CI 1.76 to 4.10), atrial septal defects (RR 2.07, 95% CI 1.26 to 3.39), and respiratory system defects (RR 2.65, 95% CI 1.32 to 5.32). CONCLUSIONS: The evidence suggests a generally small risk of congenital malformations and argues against a substantial teratogenic effect of SSRIs. Caution is advisable in making decisions about whether to continue or stop treatment with SSRIs during pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, the results showed that the association between antidepressant use and adverse health outcomes was not supported by robust evidence and that the underlying disease likely inflated the findings in a relevant way. 39,44”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, the results showed that the association between antidepressant use and adverse health outcomes was not supported by robust evidence and that the underlying disease likely inflated the findings in a relevant way. 39,44”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“The convincing evidence level was not confirmed when confounding by indication was considered, suggesting that the association between antidepressant use and autism as well as suicidality in youth and other outcomes may be due to the underlying disease rather than to the use of antidepressants, 39,43,44,50 as shown in a recent umbrella review on risk factors for autism.86”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2014) · Medical Entomology and Zoology · Cited by 17,633
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Grote, N. K., Bridge, J. A., Gavin, A. R., Melville, J. L., Iyengar, S., & Katon, W. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.111 · Cited by 1,882
Odutayo, A., Wong, C. X., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. A. (2016) · BMJ · doi:10.1136/bmj.i4482 · Cited by 867
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Research works printed but not linked: 3
- U.S Food and Drug Administration (FDA). Public Health Advisory: Paroxetine. 2005. https://wayback.archive-it.org/7993/20170112033310/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm . Accessed 27 Aug 2018.; 2018.
- Kowalik E, Ward K, Ye Y. SSRI use in pregnancy and congenital heart defects: a metaanalysis of population-based cohort studies. Pharmacotherapy. 2016;36(12):e302.
- Rothman KJ. Development DD. Modern Epidemiology. 3rd ed; 2014.
Cited by
Perinatal mental health: a review of progress and challenges
Howard, L. M., & Khalifeh, H. (2020) · World Psychiatry · doi:10.1002/wps.20769 · Cited by 1,118
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review
Dragioti, E., Solmi, M., Favaro, A., Fusar-Poli, P., Dazzan, P., Thompson, T., Stubbs, B., Firth, J., Fornaro, M., Tsartsalis, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.2859 · Cited by 215
Environmental Risk Factors for Congenital Heart Disease
Kalisch-Smith, J. I., Ved, N., & Sparrow, D. B. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037234 · Cited by 177
Metadata
- Authors
- Gao, S.-Y., Wu, Q.-J., Sun, C., Zhang, T.-N., Shen, Z.-Q., Liu, C.-X., Gong, T.-T., Xu, X., Ji, C., Huang, D.-H., Chang, Q., & Zhao, Y.-H.
- Affiliations
- China Medical University (CN)
- Sheng Jing Hospital (CN)
- Venue
- BMC Medicine
- Published
- 2018-11-12
- Volume
- 16
- Issue
- 1
- Pages
- 205-205
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC6231277
- OpenAlex
- W2899847685
- Cited by
- 152
- References
- 87
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 33 · 2023: 12 · 2022: 23 · 2021: 19 · 2020: 24 · 2019: 9
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key R&D Program of China (2017YFC0907400)
- the Science and Technology Project of Liaoning Province (2013225079)
- the Doctoral Start-Up Foundation of Liaoning Province (201501007)
- the Natural Science Foundation of China (81602918)
- the Younger research fund of Shengjing Hospital (2014sj09)
- Capital Foundation of Medical Development (YQ20170002)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- selective serotonin reuptake inhibitors, maternal antidepressant use, early pregnancy, congenital malformations, congenital heart disease, major congenital malformations, paroxetine, citalopram, fluoxetine, confounding by indication, psychiatric disorders in pregnancy, prenatal drug exposure, pregnancy outcomes
- MeSH terms
- Abnormalities, Drug-Induced, Female, Humans, Infant, Pregnancy, Pregnancy Trimester, First, Risk, Cohort Studies, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. https://app.cochat.ai/papers/10.1186/s12916-018-1193-5
- The paper
- Gao, S.-Y., Wu, Q.-J., Sun, C., Zhang, T.-N., Shen, Z.-Q., Liu, C.-X., Gong, T.-T., Xu, X., Ji, C., Huang, D.-H., Chang, Q., & Zhao, Y.-H. (2018). Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Medicine. https://doi.org/10.1186/s12916-018-1193-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.